Ten years’ clinical experience with biosimilar human growth hormone: a review of efficacy data

In 2006, the European Medicines Agency (EMA) approved Omnitrope(®) as a biosimilar recombinant human growth hormone (rhGH), on the basis of comparable quality, safety, and efficacy to the reference medicine (Genotropin(®), Pfizer). Data continue to be collected on the long-term efficacy of biosimila...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Siguero, Juan Pedro, Pfäffle, Roland, Chanson, Philippe, Szalecki, Mieczyslaw, Höbel, Nadja, Zabransky, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439972/
https://www.ncbi.nlm.nih.gov/pubmed/28553079
http://dx.doi.org/10.2147/DDDT.S130320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439972/
https://www.ncbi.nlm.nih.gov/pubmed/28553079
http://dx.doi.org/10.2147/DDDT.S130320

Ejemplares similares